The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.

New study shows dementia patients who are on antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

The American Heart Association issued a scientific statement highlighting the significance of mental health in maternal CV ...

Starting today, people with Parkinson's disease will have a new treatment option, thanks to U.S. Food and Drug Administration approval of groundbreaking new technology.

A recently retired U.S. senator is calling on the Arizona legislature to pass a bill to fund clinical trials into ibogaine, ...

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

Synbio International Inc. secures rights to conduct clinical trials for AI-powered depression screening technology (NIMS: Non-invasive Mental Screening).NIMS is a fast, highly accurate and cost-effect ...